Literature DB >> 11863377

Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset.

Abbas Parsian1, Brad Racette, L Jane Goldsmith, Joel S Perlmutter.   

Abstract

Idiopathic Parkinson's disease (PD) is an age-dependent, neurodegenerative condition frequently associated with dementia. Although it is predominantly a sporadic disease, 20-30% of cases are familial, suggesting a complex mode of inheritance. Apolipoprotein E (APOE) allele epsilon4 has been associated with familial and sporadic late-onset senile dementia of the Alzheimer's type. To investigate the role of this gene in the development of dementia associated with PD and age at onset of PD, we evaluated the frequency of APOE gene polymorphism in a sample of PD patients with (n=118) and without (n=167) a family history, as well as matched normal controls (n=96). The PD sample was categorized according to age at onset and presence or absence of dementia. Kaplan-Meier survival analysis was used to plot genotype-specific age at onset distribution curves. Allele frequencies of APOE in PD patients with and without a family history and normal controls were not significantly different. APOE genotypes were also similar between the groups. However, the frequencies of epsilon4 allele and epsilon4/- genotype in the PD group with dementia were more than twofold higher than in normal controls, and the differences were statistically significant. There were no differences in the allele and genotype frequencies of the APOE gene between PD groups with different age at onset. The familial PD had significantly earlier age at onset than sporadic PD (Log-rank test, P=0.027). The age at onset distribution curves for different genotype groups were similar, and their differences were not statistically significant (P=0.38). After the Bonferroni's correction for multiple tests, the positive results are not significant at the P<0.05 level. We conclude that APOE does not play an important role in susceptibility to PD or age at onset of PD, but may play a role in dementia associated with PD in our sample.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11863377     DOI: 10.1006/geno.2002.6707

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  20 in total

Review 1.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

2.  APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson's disease in a Japanese population.

Authors:  Chikako Kiyohara; Yoshihiro Miyake; Midori Koyanagi; Takahiro Fujimoto; Senji Shirasawa; Keiko Tanaka; Wakaba Fukushima; Satoshi Sasaki; Yoshio Tsuboi; Tatsuo Yamada; Tomoko Oeda; Takami Miki; Nobutoshi Kawamura; Nobutaka Sakae; Hidenao Fukuyama; Yoshio Hirota; Masaki Nagai
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

3.  Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia.

Authors:  Shinsuke Fujioka; Christina Sundal; Audrey J Strongosky; Monica Case Castanedes; Rosa Rademakers; Owen A Ross; Carles Vilariño-Güell; Matthew J Farrer; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2012-11-04       Impact factor: 17.088

Review 4.  What can biomarkers tell us about cognition in Parkinson's disease?

Authors:  Brit Mollenhauer; Lynn Rochester; Alice Chen-Plotkin; David Brooks
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

5.  APOE genotype regulates pathology and disease progression in synucleinopathy.

Authors:  Albert A Davis; Casey E Inman; Zachary M Wargel; Umber Dube; Brittany M Freeberg; Alexander Galluppi; Jessica N Haines; Dhruva D Dhavale; Rebecca Miller; Fahim A Choudhury; Patrick M Sullivan; Carlos Cruchaga; Joel S Perlmutter; Jason D Ulrich; Bruno A Benitez; Paul T Kotzbauer; David M Holtzman
Journal:  Sci Transl Med       Date:  2020-02-05       Impact factor: 17.956

6.  Genetic influences on cognitive decline in Parkinson's disease.

Authors:  James F Morley; Sharon X Xie; Howard I Hurtig; Matthew B Stern; Amy Colcher; Stacy Horn; Nabila Dahodwala; John E Duda; Daniel Weintraub; Alice S Chen-Plotkin; Vivianna Van Deerlin; Dana Falcone; Andrew Siderowf
Journal:  Mov Disord       Date:  2012-02-16       Impact factor: 10.338

7.  APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.

Authors:  Thomas F Tropea; Sharon X Xie; Jacqueline Rick; Lana M Chahine; Nabila Dahodwala; Jimit Doshi; Christos Davatzikos; Leslie M Shaw; Vivianna Van Deerlin; John Q Trojanowski; Daniel Weintraub; Alice S Chen-Plotkin
Journal:  Mov Disord       Date:  2017-11-23       Impact factor: 10.338

8.  Impact of apoE deficiency during synaptic remodeling in the mouse olfactory bulb.

Authors:  Ikemefuna Nwosu; Salina Gairhe; Robert G Struble; Britto P Nathan
Journal:  Neurosci Lett       Date:  2008-06-11       Impact factor: 3.046

Review 9.  Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  Neuron       Date:  2012-12-06       Impact factor: 17.173

Review 10.  Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.

Authors:  Yadong Huang; Robert W Mahley
Journal:  Neurobiol Dis       Date:  2014-08-27       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.